Guide: Allergy and COVID-19 Vaccination

14 April 2021:   

This Guide has been developed by ASCIA, based on the current knowledge regarding COVID-19 vaccines, and is updated when new information is available. There is no evidence that people with allergy and other immune system disorders are at any greater risk of COVID-19 vaccine allergy than the general population.

pdfASCIA HP Guide Allergy COVID-19 Vaccination 2021-04-1497.57 KB

1. Vaccinate without additional precautions

Vaccinate in the community as per national recommendations, with a post-vaccination observation period of 15 minutes. This includes people with:

  • History of allergy, including anaphylaxis to food, drugs, venom, or latex.
  • Allergic conditions, including asthma, atopic dermatitis (eczema) or allergic rhinitis (hay fever).

2. Vaccinate with precautions*

  • Immediate (within four hours) and generalised symptoms of a possible allergic reaction without anaphylaxis to a previous dose of a COVID-19 vaccine.
  • Generalised allergic reaction (without anaphylaxis) to one of the ingredients in the COVID-19 vaccine to be administered (Pfizer-PEG or AstraZeneca-Polysorbate 80).
  • Prior history of anaphylaxis to previous vaccines and/or multiple drugs (injectable and/or oral) where ingredients such as PEG or polysorbate 80 may conceivably be the cause.
  • A known systemic mast cell activation disorder with raised mast cell tryptase, that requires treatment.

* Precautions:

  • Review or discussion prior to vaccination by a clinical immunology/allergy or vaccinology specialist, to develop a risk/benefit assessment for each patient.
  • Skin testing to the vaccine and/or graded doses should be considered in some cases.
  • Vaccination in a medical facility equipped for the management of anaphylaxis (such as a medical clinic with multiple doctors available, or a hospital clinic).
  • Post-vaccination observation period should be at least 30 minutes.

3. Vaccination contraindicated

  • Documented anaphylaxis to one of the ingredients contained in the COVID-19 vaccine to be administered (Pfizer – PEG or AstraZeneca - Polysorbate 80).
  • Anaphylaxis to a prior dose of a COVID-19 vaccine.

COVID-19 vaccine side effects indicate the start of an immune response, not an allergic reaction.

  • Some people will get mild, short-term side effects from vaccination, including injection site reactions, fever, joint pain, muscle aches, fatigue, headaches, or worsened eczema a day after vaccination.
  • These common side effects indicate the start of an immune response, not an allergic reaction, which are rare. Side effects do not usually require treatment other than paracetamol for fever or discomfort.

Note:

  • Anaphylaxis with one type of COVID-19 vaccine may not preclude vaccination with another vaccine, but this should only occur if the precautions listed above are met. If there is a high risk of an allergic reaction to one of the vaccines (e.g. known allergy to PEG or Polysorbate 80), it may be possible to have another vaccine which does not contain the ingredient, subject to availability and medical advice.
  • A statement from the Australian Technical Advisory Group on Immunisation (ATAGI) about AstraZeneca COVID-19 vaccine safety concerns is available at www.health.gov.au/news/atagi-statement-on-astrazeneca-vaccine-in-response-to-new-vaccine-safety-concerns 
  • For more information refer to the ASCIA website www.allergy.org.au/members/covid-19#cd1

© ASCIA 2021

ASCIA is the peak professional body of clinical immunology/allergy specialists in Australia and New Zealand

Mod ASCIA Member
Donate to AIFA
go to NAS website
About ASCIA

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links

About ASCIA

ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.

Accreditiation

healthdirect

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.